Joslyn S. Kirby - Concepedia

Author

Joslyn S. Kirby

Penn State Milton S. Hershey Medical Center ORCID

Also Known As

J Kirby, J. Kirby, J. S. Kirby, J. Sciacca Kirby, J., Kirby, J.S. Kirby, Jane Kirby, Joshuo A. Kirby, Joslyn Kirby, Joslyn R. S. Kirby

227

Publications

4.7K

Citations

H-Index

Concepts

All Affiliations

Penn State Milton S. Hershey Medical Center Zealand University Hospital Cardiff University Pennsylvania State University Ruhr University Bochum

About

Joslyn S. Kirby is an author at Penn State Milton S. Hershey Medical Center specializing in medicine, dermatology, and pathology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	14	16	840
2	Health Sciences	2	2	31
3	Education	1	1	28
4	Public Health	1	1	268
5	Allergy	1	1	22

Joslyn S. Kirby

Publications

2.7K

Citations

H-Index

Page 1

	Year	Citations
Sex- and Age-Adjusted Population Analysis of Prevalence Estimates for Hidradenitis Suppurativa in the United States Amit Garg, Joslyn S. Kirby, Jonathan Lavian, JAMA Dermatology	2017	371
Evaluating patients' unmet needs in hidradenitis suppurativa: Results from the Global Survey Of Impact and Healthcare Needs (VOICE) Project Amit Garg, Erica Neuren, Denny Cha, Journal of the American Academy of Dermatology Health PolicyGlobal SurveyPatient SafetyInternational HealthOutcomes Research	2019	268
A core domain set for hidradenitis suppurativa trial outcomes: an international Delphi process Linnea Thorlacius, John R Ingram, Bente Villumsen, British Journal of Dermatology	2018	165
Efficacy and Safety of Adalimumab in Conjunction With Surgery in Moderate to Severe Hidradenitis Suppurativa Falk G. Bechara, Maurizio Podda, Errol P. Prens, JAMA Surgery	2021	141
Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials Alexa B. Kimball, Gregor B. E. Jemec, Christopher J. Sayed, The Lancet Moderate-to-severe Hidradenitis SuppurativaBe Heard IiBe HeardClinical DermatologyDermatology	2024	128
Health Care Utilization Patterns and Costs for Patients With Hidradenitis Suppurativa Joslyn S. Kirby, Jeffery J. Miller, David R. Adams, JAMA Dermatology	2014	117
The Hidradenitis Suppurativa Quality of Life (HiSQOL) score: development and validation of a measure for clinical trials Joslyn S. Kirby, Linnea Thorlacius, Bente Villumsen, British Journal of Dermatology	2019	104
Standardized laboratory monitoring with use of isotretinoin in acne Timothy J. Hansen, Saramarian Lucking, Jeffrey J. Miller, Journal of the American Academy of Dermatology MedicineBioanalysisClinical DermatologyToxicologyDermatology	2016	84
Janus kinase 1 inhibitor <scp>INCB054707</scp> for patients with moderate‐to‐severe hidradenitis suppurativa: results from two phase <scp>II</scp> studies* Afsáneh Alavi, Iltefat Hamzavi, Kurt Brown, British Journal of Dermatology	2022	81
Association of Resilience With Depression and Health-Related Quality of Life for Patients With Hidradenitis Suppurativa Joslyn S. Kirby, Melissa Butt, Solveig Esmann, JAMA Dermatology	2017	79

Page 1